Generic Drug Leaders and Their Unique Growth Strategies
Generic Drug Leaders and Their Unique Growth Strategies
Despite increasing competition in the pharmaceutical industry, several generic drug companies are poised for growth.
Though generic drugs represent more than 90% of dispensed prescriptions, generic drug manufacturers continue to face pressure from drug distributors, pharmacy benefit managers, and competitors. But this reality doesn’t necessarily mean investors should overlook the generic drug pharmaceutical industry—in fact several leading companies are diversifying their assets for future growth.
Our latest report analyzes the US generic drug landscape, including an industry overview, historical data, deep dives into generic leaders—such as Teva, Sandoz, and Viatris—and more.
Download the report to learn how to leverage these top companies’ growth plans for your investing strategy.
What's Inside
What's Inside
- An in-depth overview of the history of generic drugs and their relationship to the FDA and US government
- A comprehensive analysis of how Teva, Sandoz, and Viatris are strengthening their positions in the generics industry
- Future company growth forecasts from Morningstar experts